repaglinide has been researched along with glucagon-like peptide 1 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Feinglos, MN; Hughes, AT; Luna, B | 1 |
| Bain, SC; Bodvarsdottir, TB; Bracken, RM; Deacon, CF; Dunseath, G; Holst, JJ; Lowe, GD; Luzio, S; Prior, SL; Rumley, A; Stephens, JW; Wareham, K | 1 |
| Bailey, T | 1 |
| Meillet, L | 1 |
| Hidaka, S; Seino, S; Seki, C; Takahashi, H; Yokoi, N | 1 |
| Gnesin, F; Hemmingsen, B; Kähler, LKA; Madsbad, S; Thuesen, ACB | 1 |
3 review(s) available for repaglinide and glucagon-like peptide 1
| Article | Year |
|---|---|
The use of insulin secretagogues in the treatment of type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Piperidines; Protein Precursors; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Topics: Algorithms; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Metformin; Peptides; Piperidines; Practice Guidelines as Topic; Receptors, Glucagon; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2013 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Myocardial Infarction; Piperidines; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Sulfonylurea Compounds | 2020 |
1 trial(s) available for repaglinide and glucagon-like peptide 1
| Article | Year |
|---|---|
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; E-Selectin; F2-Isoprostanes; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Metformin; Middle Aged; Oxidative Stress; Piperidines; Postprandial Period; Time Factors; Treatment Outcome; Wales | 2011 |
2 other study(ies) available for repaglinide and glucagon-like peptide 1
| Article | Year |
|---|---|
[New medications for patients with type 2 diabetes].
Topics: Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Piperidines | 2014 |
Characteristics of repaglinide effects on insulin secretion.
Topics: Animals; Calcium; Carbamates; Drug Interactions; Exocytosis; Glucagon-Like Peptide 1; Guanine Nucleotide Exchange Factors; Insulin; Insulin Secretion; Insulin-Secreting Cells; Intracellular Space; Mice; Mice, Inbred C57BL; Piperidines | 2018 |